What I have not seen mentioned yet is the importance of the final statement regarding the patent - it has now been transfered to CTIX. We don't know how long litigation has been ongoing with the two private parties and no doubt it was not appropriate to discuss litigation about a patent not owned by CTIX. Well, now CTIX retains the value of the molecule they are spending resources on prooving - this is HUGE. Only now can big pharma discuss making arrangements with CTIX as the patent owner. This is my interpretation of this great news - litigation over, CTIX can finally have K for real. I thank Menon for keeping this a private matter and not exposing us shareholders to the unknown liability regarding the patent.